First-in-Human BI 4015092 Trial Takes Aim at KRAS G12D–Driven Solid Tumors
Boehringer Ingelheim has opened a phase 1 program around BI 4015092, a first-in-human investigational therapy designed for adults with advanced or metastatic solid tumors carrying a KRAS G12D mutation. The study is built to answer the questions that matter first in early drug development: how much of the drug patients can tolerate, what the body does to the drug, whether the drug engages its intended biology, and whether any early antitumor activity emerges in a molecularly selected population that has exhausted standard options.
The trial is open-label and multicenter, and it allows enrollment across a broad range of advanced solid tumors, with explicit attention to colorectal cancer and pancreatic ductal adenocarcinoma. The design reflects a straightforward biologic premise. KRAS G12D is one of the most consequential oncogenic alterations in solid tumor biology, and tumors that carry it often remain dependent on downstream signaling pathways that can be difficult to suppress with existing therapies. A direct inhibitor strategy, especially one tested first in humans in a mutation-defined population, is intended to challenge that dependence at its source.
This is an early study, not a finished clinical answer. Even so, the structure of the protocol reveals where investigators believe the pressure points lie: dose, tolerability, pathway inhibition, and whether the signal improves when the drug is paired with cetuximab, an established EGFR-targeted antibody.
Dose Escalation Will Define the Starting Safety Boundary
The trial begins with monotherapy dose escalation in adults with advanced or metastatic KRAS G12D-mutant solid tumors who have already received and failed standard therapy, or who cannot receive approved options because of intolerance or ineligibility. Small groups will receive BI 4015092 alone while the dose is increased stepwise to identify a tolerable range.
That opening phase is the gatekeeper for the rest of the program. In first-in-human oncology studies, dose escalation is where the field learns whether the molecule behaves like a viable drug or stalls at the intersection of toxicity and target engagement. For a KRAS-directed agent, the central concern is not only whether adverse effects appear, but whether biologically active exposure can be achieved without forcing dose reductions that would blunt the antitumor hypothesis.
A separate monotherapy expansion includes cohorts with advanced KRAS G12D-mutant pancreatic ductal adenocarcinoma and colorectal cancer. In pancreatic cancer, eligibility extends to patients who have progressed or recurred after at least one prior line of standard chemotherapy for advanced or metastatic disease, with specific rules for prior neoadjuvant or adjuvant therapy if recurrence occurred during treatment or within 6 months of completion. In colorectal cancer, eligibility requires prior progression or recurrence after at least one standard line of therapy.
Combination Work Tests Whether EGFR Blockade Can Strengthen KRAS Suppression
The protocol then moves into combination testing, pairing BI 4015092 with cetuximab. Dose escalation in the combination arm will again seek a suitable dose, this time for the dual regimen. A randomized dose-expansion portion follows, with participants assigned by chance to different BI 4015092 dose levels alongside cetuximab.
This combination strategy is biologically familiar in KRAS-targeted development. EGFR signaling can feed into MAPK pathway reactivation and adaptive resistance, especially in colorectal cancer, where upstream receptor signaling has repeatedly limited durable pathway suppression. Adding cetuximab is a rational attempt to reduce escape routes that might otherwise allow the tumor to re-ignite downstream signaling even when KRAS itself is being pharmacologically pressured.
The combination arm is restricted to advanced or metastatic KRAS G12D-mutant colorectal cancer. That narrower focus likely reflects the tumor-specific signaling dependence seen in colorectal disease, where EGFR blockade has a stronger mechanistic footing than in many other solid tumors. The study design suggests investigators want to learn not just whether the drug can be given with cetuximab, but whether the pairing can reshape response in a disease that has long been difficult to hold in check after standard treatments fail.
A clean safety profile will matter as much as any response signal. Two targeted agents can deepen pathway suppression, but they can also compound toxicity, narrowing the window between pharmacologic effect and clinical tolerability. If the combination proves active, dose selection will still have to preserve enough exposure to matter in the real world.
Molecular Selection Narrows the Trial to a Difficult-to-Treat Population
Only adults with histologically or cytologically confirmed locally advanced or metastatic solid tumors carrying a locally detected KRAS G12D mutation can enter the study. Participants must also provide written informed consent before trial-specific procedures. Across the protocol, the population is defined by prior treatment failure, intolerance, or lack of suitability for established therapies, which means the study is not testing an earlier-line substitution. It is probing a molecularly defined salvage setting where unmet need is already high.
This matters because KRAS G12D is not merely a biomarker for eligibility; it is the organizing principle of the entire development program. The mutation identifies tumors that may share a dependency on a specific oncogenic driver, even when the primary tumor site differs. In practice, that creates a chance to test a common mechanism across distinct histologies while still preserving disease-specific expansion cohorts for pancreatic and colorectal cancer.
Participants may remain in the study as long as they continue to benefit and can tolerate treatment. During regular site visits, investigators will monitor health, adverse events, tumor size, and evidence of spread. Those repeated assessments will determine whether the drug class can move beyond tolerability and into the more demanding territory of durable disease control.
A 200-Patient Phase 1 Program Spanning Four Countries
The estimated enrollment is 200 patients, and the study is listed as phase 1 with a start date of 2026-12-07 and an estimated completion date of 2032-11-05. The trial is open across 11 locations in the United States, Australia, Japan, South Korea, and Spain, including Yale Cancer Center, MD Anderson Cancer Center, Samsung Medical Center, Seoul National University Hospital, and Vall d’Hebron.
The scale and geography signal a sponsor preparing for a long development arc rather than a narrow proof-of-concept exercise. Early oncology programs increasingly begin with mutation-defined cohorts and expand only if the safety and pharmacodynamic story holds. Here, the essential readout will be whether BI 4015092 can reach a usable dose, whether cetuximab adds value without unacceptable toxicity, and whether the biology of KRAS G12D remains vulnerable when both monotherapy and combination treatment are pushed into the clinic.
The most consequential unknown is still the same one that has challenged many targeted oncology programs: whether pathway inhibition translates into meaningful tumor control in patients whose cancers have already learned how to survive multiple prior therapies. The study is designed to answer that directly, and it will do so first through safety and dosing, not through promise.